Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 71.63
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. Its products include ready to fill pellets, mup's tissue bio adhesive, injectables, oral solid dosages, oral solid dosages, and liquid orals. The company was founded on April 24, 1995 and is headquartered in Hyderabad, India.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Data is available to registered users only
Buy
Sell